Sitemap - 2026 - The Oncology Shot with Timothee Olivier
The Risk of Uninformative Trials: Statistical Considerations in Radiotherapy Trials
Do we need to be reassured about surrogates? My take in The BMJ.
Currency of Influence in Oncology
My MD-Anderson Cancer Center Madrid Hospiten Talk
Not One, but Two Papers! What Daraxonrasib’s Recent Results Mean for Ongoing and Future Trials
What to look for in NATALEE’s 6-year overall survival results: post-protocol care.
The forgotten question: does each drug actually matter?
My Fribourg talk, in French! Statistics in Oncology in Practice
A Cultural Gap: How Many Patients With Metastatic Pancreatic Cancer Do Not Start Systemic Therapy?
“Chemo‑free” is not always better: the FDA withdrawal of adagrasib in colorectal cancer
Daraxonrasib Is FDA-Approved: Both Good News and Bad News
Beyond Cross-Trial Comparisons: What Digitized Survival Curves Can Really Tell Us
Sham Controls and Tumor Treating Fields: Does the Ethical Argument Hold?
Additional Insights Into Early Daraxonrasib Data
RASolute 302 (daraxonrasib) in metastatic pancreatic cancer: a revolution?
An Eagle Eye on AQUILA Survival Data. Our New Paper Is Out. IQWiG Wins, OpenEvidence Fails.
My IQWiG lecture in Cologne! What a great audience and team!
The Imbalance of NCCN Guidelines: Quick to Implement, Slow to Let Go
Critical Appraisal in Breast Cancer: The Essentials in 30 Minutes.
The PATINA trial – palbociclib maintenance in metastatic breast cancer.